Navigation Links
Actos Lawsuit News: Bernstein Liebhard LLP Notes Latest Scheduling Order in Actos Bladder Cancer Litigation
Date:2/24/2013

New York, New York (PRWEB) February 24, 2013

Actos lawsuits continue to move forward in the federal multidistrict litigation underway in U.S. District Court, Western District of Louisiana. According to a Scheduling Order dated February 19, 2013, the Court has established a Pilot Bellwether Program, which sets up a stream-lined selection process for a minimum of two Pilot Bellwether trials. The Order stipulates that the litigation’s first Pilot Bellwether trial will begin on January 27, 2014, while the second will commence on April 14, 2014. Attorneys for both sides have been directed to nominate five Actos lawsuits each to participate in the Pilot Bellwether Discovery Pool by April 1, 2013.* (In re: Actos Product Liability Litigation, MDL No. 2299)

“The bellwether trials will provide valuable insight into how juries might weigh similar Actos claims. We look forward to this process getting underway,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm is currently offering free Actos bladder cancer lawsuit evaluations to individuals who may have been harmed by the medication.

Actos Bladder Cancer Lawsuits
Actos, known generically as pioglitazone, is approved as a treatment for type 2 diabetes. The U.S. Food & Drug Administration (FDA) ordered Takeda Pharmaceuticals to add new warnings to the Actos label in June 2011, after a study found that long-term use of the drug increased the risk for bladder cancer.* Since then, hundreds of people have filed Actos bladder cancer lawsuits alleging long-term use of the drug caused them to develop the disease.

The nation’s first trial involving an Actos bladder cancer lawsuit is now underway in Los Angeles Superior Court. According to a recent report
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. National Actos Attorneys File Lawsuit on Behalf of Louisiana Woman who Developed Bladder Cancer Allegedly Due to The Diabetes Drug Actos
2. Victim’s Rights to Recover for Actos Bladder Cancer Could Expire Soon
3. Actos Bladder Cancer Lawsuit Filed in Louisiana Alleging Woman Used Diabetes Medication and Contracted Bladder Cancer, Consumer Justice Foundation Reports
4. Researchers Offer Explanation for Actos Bladder Cancer Risk
5. New Lawsuit alleges Actos caused Bladder Cancer
6. US Drug Watchdog Now Urges Family Members Of A Diabetic Who Died From Bladder Cancer After Using The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
7. US Drug Watchdog Now Urges Users Of The Diabetes Drug Called Actos To Call The Johnson Law Group if They Have Developed Bladder Cancer-Time Is Of The Essence
8. US Drug Watchdog Now Urges Any US Citizen Who Used the Diabetes Drug Called Actos and Then Developed Bladder Cancer To Contact The Johnson Law Group For A Legal Review
9. US Drug Watchdog Now Urges Loved Ones Of A Diabetic Who Died From Bladder Cancer Who Had Used The Diabetes Drug Called Actos To Call The Johnson Law Group Immediately
10. US Drug Watchdog Now Expands Their Efforts to Educate Diabetics About the Diabetes Drug Actos and Bladder Cancer, with the Suggestion Victims Call the Johnson Law Group
11. US Drug Watchdog Now Urges Any Diabetic Who Used the Diabetes Drug Actos and Now Have Been Diagnosed with Bladder Cancer to Call The Johnson Law Group-ASAP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2014)... The risk of pregnancy among women using a ... more than 10 times greater over a 10-year period ... study by researchers at Yale University and UC Davis ... medical journal Contraception , the study found the ... marketed under the brand name Essure. , "This ...
(Date:4/22/2014)... release is available in German . ... important intracellular signaling molecules, but their mode of action ... of cellular function and behavior, while at high concentrations ... and DNA. To analyze how redox signaling unfolds in ... microscopy technique has been developed jointly by the teams ...
(Date:4/22/2014)... Nearly 7 in 10 Americans support mandated ... national survey by researchers at the University of Michigan ... under the age of 18 at home, and adults ... than other adults to support universal coverage of birth ... the Journal of the American Medical Association ...
(Date:4/22/2014)... has been approved since November 2013 for the prevention ... In an early benefit assessment pursuant to the "Act ... (AMNOG), the German Institute for Quality and Efficiency in ... offers an added benefit over the appropriate comparator therapy. ... of turoctocog alfa is not proven. As no relevant ...
(Date:4/22/2014)... intervention researchers have been informed that the National Institute ... Institutes of Health, will award an $8 million grant ... an experimental drug for stroke. , The drug, ... plasminogen activator, or rtPA the "clot-busting" drug currently ... laboratory rodent studies, 3K3A-APC, used in combination with rtPA, ...
Breaking Medicine News(10 mins):Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Neuroimaging: Live from inside the cell 2Health News:More than two-thirds of Americans support mandated coverage of birth control in health plans 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 2Health News:Turoctocog alfa in patients with hemophilia A: Added benefit not proven 3Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 2Health News:$8 million NIH grant will fund multicenter clinical trial of stroke intervention drug 3
... of a multi-faceted transcriptional complex to control of ... stem cells. Two separate studies, published by Cell ... Cell, provide insight into novel subunits associated with ... a previously undescribed chromatin function that is required ...
... M.D., Will Lead One of the Nation,s Largest ... Electrophysiology Programs, ... and Director of Cardiac Electrophysiology at,Washington University in St. Louis, has ... Institute., "We are pleased to have such an established leader ...
... largest,provider of business services to orthodontic and dental ... and Atlanta, Georgia to,better serve the company,s practices ... confirm our operating principle that the,heart of our ... in the,hundreds of practices we serve each day," ...
... 11% of international disease burden , , THURSDAY, Jan. 17 ... childhood malnutrition accounts for more than one-third of childhood ... researchers report. , "The key messages here are that ... reform is needed," lead researcher Dr. Robert Black, a ...
... adopt the World Health Organization (WHO) standard on fine particulate ... premature deaths, concludes research in the Journal of Epidemiology and ... levels of fine particulate matter pollution (PM2.5) at 20 g/m ... by the US Environmental Protection Agency is 15 g/m ...
... London, New Delhi and Singapore (January 17, 2008) ... looks set to continue its successful growth in ... partnership with the International Union for Health Promotion ... Promotion & Education. , Published quarterly, Promotion and ...
Cached Medicine News:Health News:Cancer stem cell marker also drives transcription in normal cells 2Health News:Cancer stem cell marker also drives transcription in normal cells 3Health News:Cleveland Clinic Recruits World Renowned Heart Rhythm Specialist to Direct Electrophysiology 2Health News:OrthoSynetics(TM) Opens Regional Offices in Dallas, Atlanta 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 2Health News:Malnutrition Responsible for a Third of Child Deaths Worldwide 3Health News:Europe should adopt WHO recommendations for particulate matter cuts 2
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Insulin ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong ...
(Date:1/15/2014)... 2014  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ... by its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), ... of Solta Medical, Inc. (NASDAQ: SLTM ) ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16
... Morria Biopharmaceuticals Plc, a,biopharmaceutical company focused ... announced that it has obtained regulatory,approval from ... to initiate,a Phase II study of MRX-4 ... The two-arm, randomized, multi-dose, double-blind, placebo-controlled,study includes ...
... Md., June 11 EntreMed, Inc.,(Nasdaq: ENMD ... treatment of cancer and inflammatory diseases, today,announced the ... of 2-,methoxyestradiol (2ME2). The patent grants EntreMed composition-of-matter,and ... for analogs,of 2ME2 in oncology and a broad ...
Cached Medicine Technology:Morria Biopharmaceuticals Plc Announces Regulatory Approval to Commence Phase II Clinical Study of MRX-4 in Allergic Rhinitis 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 2EntreMed Receives New Patent for 2-Methoxyestradiol Analogs 3
... The Genesis II® Total Knee System will ... far more is possible with less - ... while fully addressing both clinical and cost ... these design goals, giving surgeons creative solutions ...
Cementless hip system...
... system continues the "Consensus Concept" approach ... with the diversified experience of a ... an affordable knee system that incorporates ... designed to provide both joint and ...
... Foundation® Modular Revision System offers a femoral ... specially designed cam action that engages at ... smooth stable femoral roll-back motion and allow ... tibial insert in conjunction with the femur ...
Medicine Products: